AI Enables Personalized Treatment of Myocarditis

Myocarditis (inflammation of the heart muscle) is usually caused by viruses, e.g. in COVID-19 disease. However, it can also be induced by medication, toxic substances or in the context of a rheumatological disease. Clinical assessment is difficult due to widely varying symptoms, from fatigue to chest pain, palpitations, shortness of breath, and, rarely, sudden cardiac death, the latter associated with sports activity. Nowadays, cardiac magnetic resonance imaging (CMR) is usually performed when myocarditis is suspected. In some cases the data obtained from these scans do not provide a sufficiently personalized risk assessment and respective optimal treatment options.

Review study points to new approaches

In a scientific review in collaboration with the University of Tübingen, the Bristol Heart Institute and Harvard Medical School, a research group led by Prof. Christoph Gräni, MD, PhD, from Inselspital and the University of Bern assessed various CMR parameters in terms of their importance for diagnosis, prognosis and monitoring of myocarditis.

"From the comparison of the different used diagnostic tools, we can derive novel approaches for future research and development. Next, we will determine how artificial intelligence (AI) can assist us in a rapid and comprehensive evaluation of the many different clinical parameters and image data," according to Christoph Gräni. "To this end, I am pleased that we have received funding from the Bern Center for Artificial Intelligence in Medicine (CAIM) to pursue this promising research direction."

Making complex cardiac function data readable with AI

Using CMR, more than 1000 measurements can be collected per patient, including parameters on anatomy, tissue characterization of the heart muscle and pericardium (e.g., inflammation or scars), and heart muscle function data. Physicist Yasaman Safarkhanlo, who is a PhD student under the supervision of Prof. Gräni at the Department of Cardiology at the Inselspital, explains: "Only AI can evaluate these many variables quickly in their entirety. We want to let the data speak to better understand what exactly happens during myocarditis. This is a novel approach that does not start from our previous understanding of physiology and looks for a known feature in the images. With our project, we're rather starting from the data aspect to see what new correlations we discover on the images - so, ultimately, we can allow better treatment in the future."

Personalized counseling of athletes

The researchers' objective is to develop evaluation tools that can be used to determine whether myocarditis will heal spontaneously and sustainably or whether close monitoring is needed. "Athletes in particular could be better advised in this way: On the one hand, the goal is to avoid sudden cardiac death, but on the other hand, to not unnecessarily restrict athletes in their activity," Gräni explains. In this respect, all clinical data and image data will one day flow into the Insel Gruppe's digital clinical information and control system (KISS), where they will be automatically evaluated in order to provide the treating physician with a probability of diagnosis, a prediction of the course of the disease, and an optimal therapy suggestion.

Focus on digitalization and AI applications in medicine

The Department of Cardiology's commitment to using the latest digital technologies for personalized medicine is timely with the strategic digitalization projects at the Insel Gruppe and the University of Bern. "The Faculty of Medicine of the University of Bern is strongly committed to digitalization in medical education and research. With the establishment of the Center for Artificial Intelligence in Medicine (CAIM) the university and the Insel Guppe have created an excellent research platform. It allows utilizing the latest developments in cutting-edge digital technology and artificial intelligence for personalized treatment approaches and to anchor this knowledge in education and training," says Prof. Claudio Bassetti, MD, Dean of the University's Faculty of Medicine and Director and Chief Physician of the Department of Neurology at Inselspital.

CAIM selects myocarditis project for research funding

During the recent first round of CAIM's research funding, the myocarditis project was selected along with four others and will receive CHF 100 000.- CAIM director Prof. Raphael Sznitman says: "It is a tremendous asset to have clinicians from the Inselspital and technical scientists from the University working closely together here in Bern. By bringing dynamic and driven individuals to reach beyond their trained disciplines, the potential for innovation and its impact on our healthcare system is simply limitless. This is at the core of CAIM and we are very excited to see such partnerships thrive and look forward to partnering with the Department of Cardiology at Inselspital."

Christian Eichhorn, Simon Greulich, Chiara Bucciarelli-Ducci, Raphael Sznitman, Raymond Y Kwong, Christoph Gräni.
Multiparametric Cardiovascular Magnetic Resonance Approach in Diagnosing, Monitoring, and Prognostication of Myocarditis.
JACC: Cardiovascular Imaging, 2022. doi: 10.1016/j.jcmg.2021.11.017

Most Popular Now

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...

MEDICA and COMPAMED 2024: Shining a Ligh…

11 - 14 November 2024, Düsseldorf, Germany. Christian Grosser, Director Health & Medical Technologies, is looking forward to events getting under way: "From next Monday to Thursday, we will once again...

In 10 Seconds, an AI Model Detects Cance…

Researchers have developed an AI powered model that - in 10 seconds - can determine during surgery if any part of a cancerous brain tumor that could be removed remains...